Losmapimod (LOSM), an orally active p38 MAPK inhibitor, is an anti-inflammatory agent with cardioprotective effects. Nevertheless, the effect of LOSM against DOX-induced cardiotoxicity has not been ...

The BRAFV600 mutation is found in about 50% of melanomas, and patients whose tumors harbor this mutation are often treated with MAPK inhibitors, which target the tumor's growth pathway.

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

Effective induction of apoptosis can be achieved through inhibition or interference with Mcl-1. Thus, this mini review discusses existing Mcl-1 inhibitors. Figure 2. NSC260594 can regulate Mcl-1 ...

How do PARP inhibitors work? PARP is a protein (enzyme) found in our cells, it stands for poly-ADP ribose polymerase. It helps damaged cells to repair themselves. As a cancer treatment, PARP ...

Int Ophthalmol Clin. 2015;55(1):45-51.

dahliae infection was elucidated by high-throughput sequencing technology. KEGG pathway analysis revealed that the upregulated genes in resistant cultivars were significantly enriched in the MAPK ...

Join Labroots for the highly anticipated 12th Annual Cancer Research & Oncology Virtual Event Series on October 2nd, 2024. This event will unite esteemed academic and industry experts and medical ...

(NASDAQ: KTTA), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor ... of PAS-004 in patients with MAPK pathway driven advanced solid tumors ...